Senior Manager, Department of pharmacology and toxicology, Innoventbio.Inc
Key industry shortage of talents in Suzhou, Associate senior engineer of bio-medicine in Suzhou
Graduated from Institute of Biophysics, Chinese Academy of Sciences, the major is basic immunology. PhD work has been published in nature communications (IF=16.6)
Participated in the early development of Innoventbio marketed drugs, Sintilimab (IBI308), Tafolecimab (IBI306), IBI363, IBI343, IBI389 and other programs after joined Innoventbio at 2017，
Published 5+ publications as first author or corresponding author: Nature Cancer (IF=23.2), Cell Reports Medicine (IF=14.4), mAbs (IF=6.4), Cancer Immunology Immunotherapy (IF=5.4) etc
信达生物制药高级经理
信达生物制药集团国清院药理与毒理部-体内药理高级经理
姑苏重点产业紧缺人才，苏州市生物医药工程专业副高级职称
博士毕业于中国科学院生物物理研究所，从事基础免疫相关科学研究。博士工作发表在nature communications (IF=16.6)上
2017年加入信达生物制药，参与信达上市药物达伯舒 (IBI308)，托莱西单抗(IBI306), IBI363，IBI343，IBI389等项目的开发
目前以第一作者或者通讯作者参与了5+篇文章，发表在Nature Cancer (IF=23.2), Cell Reports Medicine (IF=14.4), mAbs (IF=6.4), Cancer Immunology Immunotherapy (IF=5.4)等
姑苏重点产业紧缺人才，苏州市生物医药工程专业副高级职称
博士毕业于中国科学院生物物理研究所，从事基础免疫相关科学研究。博士工作发表在nature communications (IF=16.6)上
2017年加入信达生物制药，参与信达上市药物达伯舒 (IBI308)，托莱西单抗(IBI306), IBI363，IBI343，IBI389等项目的开发
目前以第一作者或者通讯作者参与了5+篇文章，发表在Nature Cancer (IF=23.2), Cell Reports Medicine (IF=14.4), mAbs (IF=6.4), Cancer Immunology Immunotherapy (IF=5.4)等